RPG Life Sciences Ltd

RPG Life Sciences Ltd has experienced a notable shift in its valuation parameters, moving from an attractive to a fair valuation grade amid evolving market dynamics. This article examines the implications of changes in key valuation metrics such as the price-to-earnings (P/E) and price-to-book value (P/BV) ratios, comparing them with historical averages and peer benchmarks to assess the stock’s price attractiveness.

RPG Life Sciences Ltd touched a new 52-week low of Rs.1767.25 today, marking a significant decline in its stock price amid broader market fluctuations and sectoral underperformance. The stock has experienced a consecutive three-day fall, accumulating a loss of 6.8% over this period, reflecting ongoing pressures within the Pharmaceuticals & Biotechnology sector.

RPG Life Sciences Ltd has declined to a fresh 52-week low of Rs.1767.25, marking a significant downturn in the stock’s performance amid broader market fluctuations and sector-specific pressures. The stock has underperformed its sector and the broader market over the past year, reflecting a combination of subdued financial metrics and market sentiment.

RPG Life Sciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 16 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 04 March 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

RPG Life Sciences Ltd has recently touched a 52-week low, closing near Rs 1772.05, marking a significant decline in its stock price amid broader market weakness and sector underperformance. The stock’s recent trajectory reflects a combination of subdued financial growth and market pressures within the Pharmaceuticals & Biotechnology sector.

RPG Life Sciences Ltd has witnessed a notable shift in its valuation parameters, moving from a fair to an attractive rating, despite a recent downgrade in its overall mojo grade to Sell. This change is primarily driven by improvements in key valuation metrics such as the price-to-earnings (P/E) and price-to-book value (P/BV) ratios, positioning the stock as a more compelling option within the Pharmaceuticals & Biotechnology sector amid mixed market returns.

RPG Life Sciences Ltd is rated Sell by MarketsMOJO, with this rating last updated on 16 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 21 February 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook.

RPG Life Sciences Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a bearish trend. The company’s Mojo Grade was downgraded from Hold to Sell on 16 Jan 2026, reflecting deteriorating technical conditions amid a broader market context that has seen the stock underperform the Sensex over recent months.

RPG Life Sciences Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a transition from bearish to mildly bearish trends. Despite a recent downgrade in its Mojo Grade to Sell, the stock’s mixed technical signals and historical performance offer a nuanced outlook for investors navigating the Pharmaceuticals & Biotechnology sector.

RPG Life Sciences Ltd is rated Sell by MarketsMOJO, with this rating last updated on 16 January 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 10 February 2026, providing investors with the latest insights into the company’s performance and outlook.

RPG Life Sciences Ltd has experienced a notable shift in its technical momentum, moving from a bearish stance to a mildly bearish outlook, reflecting a complex interplay of technical indicators. Despite a recent day gain of 1.71%, the stock’s broader trend remains cautious, with mixed signals from MACD, RSI, moving averages, and other key technical tools shaping investor sentiment in the Pharmaceuticals & Biotechnology sector.

RPG Life Sciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 16 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 30 January 2026, providing investors with the latest insights into the company’s performance and outlook.

RPG Life Sciences Ltd, a key player in the Pharmaceuticals & Biotechnology sector, has seen its quality rating downgraded from 'Good' to 'Average' as of 16 January 2026, prompting a shift in its Mojo Grade from Hold to Sell. This change reflects a nuanced deterioration in several fundamental business parameters, despite the company’s strong historical returns and robust capital efficiency metrics.

RPG Life Sciences Ltd experienced a significant intraday decline on 28 Jan 2026, touching a low of Rs 1,912.7, reflecting an 8.88% drop from previous levels. The stock underperformed its sector and broader market indices, continuing a three-day losing streak amid persistent selling pressure and subdued market sentiment.

RPG Life Sciences Limited reported a sharp decline in profitability for the third quarter of FY2026, with net profit tumbling 39.95% quarter-on-quarter to ₹22.13 crores, down from ₹36.85 crores in Q2 FY26. The Mumbai-based pharmaceutical company, with a market capitalisation of ₹3,483 crores, witnessed its stock decline 2.16% to ₹2,089.30 following the results announcement, reflecting investor concerns over deteriorating margins and sequential profit compression despite stable revenue performance.